CLINICAL TRIAL OF A BETA-RECEPTOR BLOCKING AGENT (LB 46) IN MIGRAINE PROPHYLAXIS

Abstract

Twenty-four patients were treated with a beta-blocking agent (Viskén, LB 46 Sandoz) and placebo in double-blind study. The dosage of Viskén was 15 mg in 11 patients and 7.5 mg in 13 patients, and each remedy was taken for 4 weeks with an interposed 3-week “wash-out” period. There was generally no definite change in migraine attack-frequency or pattern during Viskén medication. Three patients, however, had a remarkably reduced number of attacks on Viskén. This reduction may or may not have been due to Viskén.